Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani

Parasitology Research

Volumn 112, Issue 2, 2013, Pages 825-828

  Kulshrestha, Arpita ^a   Bhandari, Vasundhra ^a   Mukhopadhyay, Rupkatha ^b   Ramesh, V ^a   Sundar, Shyam ^c   Maes, Louis ^d   Dujardin, Jean Claude ^e   Roy, Syamal ^b   Salotra, Poonam ^a  

^a SAFDARJUNG HOSPITAL   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^c BANARAS HINDU UNIVERSITY   (India)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE; RESAZURIN;

ANIMAL CELL; ARTICLE; CELL ASSAY; COLORIMETRY; CONTROLLED STUDY; DRUG MONITORING; DRUG SENSITIVITY; DRUG TOLERANCE; FLUORESCENCE ANALYSIS; FLUOROMETRY; HUMAN; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PARASITE ISOLATION; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE; VALIDATION STUDY; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; FLUOROMETRY; INDIA; LEISHMANIA DONOVANI; MACROPHAGES; MICE; OXAZINES; PARASITIC SENSITIVITY TESTS; PHOSPHORYLCHOLINE; STAINING AND LABELING; XANTHENES;

LEISHMANIA DONOVANI; NASO HEXACANTHUS;

EID: 84877296173     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-012-3212-3     Document Type: Article

References (17)

1. Boelaert M, Criel B, Leeuwenburg J, Van Damme W, Le Ray D, Van der Stuyft P (2000) Visceral leishmaniasis control: a public health perspective. Trans R Soc Trop Med Hyg 94:465-471
2. Kumar D, Kulshrestha A, Singh R, Salotra P (2009) In vitro susceptibility of field isolates of Leishmania donovani to MIL and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53:835-838
3. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180:564-567
4. Mikus J, Steverding D (2000) A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. ParasitolInt 48:265-269
5. Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mondal D, Decuypere S, Ostyn B, Prajapati VK, Sundar S, Dujardin JC, Roy S (2011) Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol 41:1311-1321
6. Murray HW (2010) Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Future Microbiol 5:1301-1303
7. Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366:1561-1577
8. Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K (2009) Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. AmJTrop Med Hyg 80:580-582
9. Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau PM (2007) Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 51:1425-1430
10. Ramesh V, Katara GK, Verma S, Salotra P (2011) Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Br J Dermatol 165:411-414
11. Ramesh V, Mukherjee A (1995) Post-kala-azar dermal leishmaniasis. Int J Dermatol 34:85-91
12. Seifert K, Escobar P, Croft SL (2010) In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 65:508-511
13. Seifert K, Matu S, Javier Perez-Victoria F et al (2003) Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22:380-387
14. Singh R, Kumar D, Ramesh V, Negi NS, Singh S, Salotra P (2006) Visceralleishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. J Infect Dis 194:302-306
15. Sundar S, Rai M (2002) Advances in the treatment of leishmaniasis. CurrOpin Infect Dis 15:593-598
16. Toté K, VandenBerghe D, Levecque S, Bénéré E, Maes L, Cos P (2009) Evaluation of hydrogen peroxide-based disinfectants in a new resazurin microplate method for rapid efficacy testing of biocides. J Appl Microbiol 107:606-615
17. Vermeersch M, da Luz RI, Toté K, Timmermans JP, Cos P, Maes L (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 53:3855-3859